An interventional study of desflurane and propofol in Lung Cancer, sponsored by Juntendo University. Active, not recruiting at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-05.
Sponsored by Juntendo University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Lung Neoplasms with a site in Japan — 27 open to participants now, 48 under way, 25 of them phase 3. Lung Neoplasms · Japan.
Among the 102 studies in Lung Neoplasms with a site in Japan, this one is the 67th largest by enrollment of the 95 interventional ones that give a count, is one of 6 that started in 2012, is one of 2 with no phase, reaches primary completion later than 0 of the 47 other live ones, and was the 35th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →27 of the 102 studies in Lung Neoplasms with a site in Japan are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Japan, United States
Ages 18+
Bristol-Myers Squibb · Sites in Japan, United States, Belgium and 10 more countries
Ages 18+
Pfizer · Sites in Japan, United States, Australia and 9 more countries
Ages 18+
Boehringer Ingelheim · Sites in Japan, Australia, China and 5 more countries
Ages 18+
Pfizer · Sites in Japan, United States, Argentina and 18 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 31 · Phase 3 44 · Phase 4 1
First in 1995; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 200 across the 95 interventional studies, 350 across the 1 observational. Of the 47 that completed or were terminated, 25 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 102 have an industry lead sponsor. The 10 most frequent:
Juntendo University is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Juntendo University has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Lung Neoplasms with a site in Japan that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06635824Phase 3GenmabTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | 2027-07-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add all 12 to your calendar (.ics) → With an account.
Among the 102 studies in Lung Neoplasms with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Which is more adequate general anesthetic agent, desflurane or propofol, for emergence and recovery time, and perioperative oxygenation in lung resection surgery?
The investigators plan to investigate the effects of desflurane on oxygenation (prevention of HPV) of OLV compare with propofol which is used in general anesthesia for lung resection.
Transesophageal echocardiography (TEE) wiill be used to measure pulmonary blood flow during surgery visible and successively. To confirm the effect of HPV by measuring the change in pulmonary blood flow. The correlation between the blood oxygen concentration and attenuation of blood flow will be investigated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1\~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
Drug: desflurane
Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1\~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
Drug: propofol
Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia. Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia.
Also known as: Suprene
Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
Also known as: Diprivan
Oxygenation
Arterial blood gases are monitored.Pulmonary blood flow is measured using transesophageal echocardiogram.
Time frame: prior to surgery to one-hour after extubation
Rapidity of Emergence From Anesthesia
Time to extubation and orientation, where the patient is.
Time frame: one minute after cessation of anethetic agents to one hour after extubation
Quality of Consiousness
quality of consciousness will be assessed using Aldrete score
Time frame: after extubation
Postoperative Nausea and Vomiting
degree of nausea and frequency of vomiting
Time frame: on the postoperative day 1
| Milestone | Desflurane | Propofol |
|---|---|---|
| Started | 40 | 40 |
| Completed | 40 | 40 |
| Not completed | 0 | 0 |
Arterial blood gases are monitored.Pulmonary blood flow is measured using transesophageal echocardiogram.
| mmHg | Desflurane | Propofol |
|---|---|---|
| Preoperative | 87.4 ± 12.0 | 85.7 ± 11.3 |
| DLV(pre) | 469.9 ± 79.8 | 483.8 ± 91.7 |
| OLV(15min) | 178.5 ± 95.0 | 214.7 ± 114.2 |
| OLV(30min) | 137.7 ± 78.2 | 161.6 ± 95.4 |
| OLV(45min) | 140.7 ± 86.6 | 171.57 ± 95.6 |
| DLV(post) | 429.9 ± 98.3 | 427.49 ± 111.6 |
| 5min after exT | 131.63 ± 44.2 | 134.88 ± 64.0 |
| 30min after exT | 125.71 ± 45.3 | 125.65 ± 32.91 |
| 60min after exT | 130.49 ± 45.0 | 137.2 ± 36.0 |
Time to extubation and orientation, where the patient is.
| seconds | Desflurane | Propofol |
|---|---|---|
| Rapidity of Emergence From Anesthesia | 252.3 ± 156.3 | 269.5 ± 142.9 |
quality of consciousness will be assessed using Aldrete score
| participants | Desflurane | Propofol |
|---|---|---|
| Quality of Consiousness | 2 | 0 |
degree of nausea and frequency of vomiting
| Participants | Desflurane | Propofol |
|---|---|---|
| Postoperative Nausea and Vomiting | 15 | 10 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Desflurane | 0/40 (0%) | 0/40 (0%) | 0/40 (0%) |
| Propofol | 0/40 (0%) | 0/40 (0%) | 0/40 (0%) |
| Age, Categorical(Participants) | Desflurane | Propofol | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 35 | 35 | 70 |
| >=65 years | 5 | 5 | 10 |
| Age, Continuous(years) | Desflurane | Propofol | Total |
|---|---|---|---|
| Mean | 64.5 ± 9.7 | 63.2 ± 6.6 | 63.8 ± 8.5 |
| Sex: Female, Male(Participants) | Desflurane | Propofol | Total |
|---|---|---|---|
| Female | 19 | 16 | 35 |
| Male | 21 | 24 | 45 |
| Race and Ethnicity Not Collected(Participants) | Desflurane | Propofol | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Desflurane | Propofol | Total |
|---|---|---|---|
| Japan | 40 | 40 | 80 |
The record gives a start of Oct 2012, a primary completion of Jun 2016 and a completion of Dec 2024. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2024, 7 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Desflurane · Propofol
Juntendo University